---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039035"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:17:28.446757+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Axsome Q2 product revenue $46.7M; Auvelity sales $27.6M, up 76% sequentially

## Summary
- Total product revenue $46.7M vs $8.8M in Q2 2022 (Auvelity $27.6M, Sunosi $19.1M).
- Net loss $67.2M ($1.54/share) vs $41.4M loss in prior year; cash $437.1M at June 30, 2023.
- Expanding Auvelity sales force from 162 to 260 reps to reach 44,000 physicians.
- Initiated FOCUS Phase 3 trial of solriamfetol in ADHD; plans Phase 3 trials in binge eating (Q4 2023) and shift work disorder (Q1 2024).
- Anticipates AXS-12 narcolepsy Phase 3 topline in Q4 2023 and AXS-05 Alzheimer's agitation data in H1 2024.

## SEC filing metadata
- accession: 0000950170-23-039035
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017023039035/0000950170-23-039035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017023039035/axsm-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039035
- JSON: https://secwatch.observer/filing/0000950170-23-039035.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039035.txt

## Key facts
- Earnings Releases
  Axsome Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $46.7 million, net income $(1.54) per share.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $46.7 million
  - Net income: $(1.54) per share
  - Result: reported results
  source text: --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Total 2Q 2023 product revenue of $46.7 million Auvelity ® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi ® 2Q 2023 net product revenue of $19.1 million Pro forma second quarter
  evidence_url: https://www.sec.gov/Archives/edgar/data/1579428/000095017023039035/0000950170-23-039035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.